It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A detailed analysis was performed of the immunomodulatory and proteomic profiles of mesenchymal stromal cells (MSCs) administered to two patients with refractory acute respiratory distress syndrome (ARDS). The respiratory, hemodynamic, and multiorgan failure resolved and multiple pulmonary and systemic inflammation markers decreased. These observations highlight the mechanistic information that can be gained from clinical experience and the value of correlating in vitro potency assessments with clinical effects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Departments of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Departments of Cardiothoracic Surgery and Anesthesia, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Departments of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
2 Department of Internal Medicine, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany
3 Departments of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
4 Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Verona, Italy
5 Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
6 Departments of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Departments of Cardiothoracic Surgery and Anesthesia, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
7 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
8 Departments of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Departments of Cardiothoracic Surgery and Anesthesia, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Exosome Diagnostics Inc., New York, New York, USA
9 Departments of Cardiothoracic Surgery, Uppsala University Hospital, Uppsala, Sweden
10 Departments of Hematology, Uppsala University Hospital, Uppsala, Sweden
11 Departments of Ludwig Institute for Cancer Research, Stockholm, Sweden
12 Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
13 Departments of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden
14 Departments of Health Sciences Research Facility, Department of Medicine, University of Vermont, Burlington, Vermont, USA
15 Departments of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden; Center for Diseases of Aging, Vaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA